Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Doxorubicin
Drug ID BADD_D00723
Description Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.
Indications and Usage Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.
Marketing Status Prescription; Discontinued
ATC Code L01DB01
DrugBank ID DB00997
KEGG ID D03899
MeSH ID D004317
PubChem ID 31703
TTD Drug ID D07VLY
NDC Product Code 72027-002; 12543-3209; 70121-1218
Synonyms Doxorubicin | Farmiblastina | Ribodoxo | Rubex | Adriamycin | Adriblastin | Adriblastine | Adriblastina | Adriablastine | Adriablastin | Adrimedac | DOXO-cell | DOXO cell | Urokit Doxo-cell | Urokit Doxo cell | Doxolem | Doxorubicin Hexal | Doxorubicin Hydrochloride | Hydrochloride, Doxorubicin | Doxorubicin NC | Doxorubicina Ferrer Farm | Doxorubicina Funk | Doxorubicina Tedec | Doxorubicine Baxter | Doxotec | Myocet | Onkodox
Chemical Information
Molecular Formula C27H29NO11
CAS Registry Number 23214-92-8
SMILES CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
CardiotoxicityTroponin I, fast skeletal muscleP48788Not Available11535996; 11109196; 10076722
CardiotoxicityCreatine kinase B-typeP07335Not Available26036690
Cell deathCaspase-3P42574T57943Not Available
Cytogenetic investigationsDNA topoisomerase 1P11387T098261997159; 1649059; 1333822; 1540962; 1596908; 1330289; 8382551; 2168279; 2168281; 1319346; 11062742; 1374671; 1646393; 7882360; 1322239; 7688316; 1659821; 8383887; 8144400; 1698546
Electrolyte imbalanceParathyroid hormone/parathyroid hormone-related peptide receptorQ03431T677108400511; 1392187; 6853131; 820624; 1169899; 231063; 6691353; 2995735
Electrolyte imbalanceOsteocalcinP02818Not Available8400511; 1392187; 6853131; 820624; 1169899; 231063; 6691353; 2995735
Myocardial disordersCaspase-3P70677Not Available25657296
Renal tubular disorderBeta-hexosaminidase subunit alphaP06865Not Available1658168; 1940584; 1436313; 7977444; 2848972; 3123518; 2831737; 6434591; 2843051; 2118039; 2460571; 1960147; 16171782; 1324141; 8160791; 8070692; 2601299; 2176953; 10416216; 2156648
Renal tubular disorderLysozyme CP61626T105861658168; 1940584; 1436313; 7977444; 2848972; 3123518; 2831737; 6434591; 2843051; 2118039; 2460571; 1960147; 16171782; 1324141; 8160791; 8070692; 2601299; 2176953; 10416216; 2156648
Skin toxicityGlutathione peroxidase 3P23764Not Available11154863
Skin toxicityPeroxiredoxin-5, mitochondrialP30044T7700911154863; 9726807; 12566827; 11594740; 11330521; 14535831; 12718433; 12751907; 9726810; 11529555
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Liver injury12.01.02.003; 09.01.07.022--Not Available
Oral herpes07.05.07.002; 11.05.02.005--Not Available
Organising pneumonia22.01.02.0080.001332%Not Available
Skin mass23.07.04.014--Not Available
Brain injury19.07.03.007; 17.11.01.0030.000139%Not Available
Anorectal discomfort07.03.03.003--Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.004--
Acute kidney injury20.01.03.0160.007460%
Traumatic lung injury22.01.02.013; 12.01.03.0030.000533%Not Available
Sensitisation08.01.05.009; 10.02.01.012--Not Available
Infection reactivation11.01.08.0480.000533%Not Available
Posterior reversible encephalopathy syndrome17.13.02.0070.001332%
Pneumocystis jirovecii pneumonia22.07.08.009; 11.03.07.0050.001865%Not Available
Candida infection11.03.03.021--
Aspergillus infection11.03.01.0040.000533%Not Available
Body temperature abnormal13.15.01.0300.000533%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000347%
Acute pulmonary histoplasmosis11.03.06.002; 22.07.08.0100.000533%Not Available
Biliary fistula09.02.03.0050.000799%
Breast cancer recurrent21.05.01.017; 16.10.01.0090.001066%Not Available
Cardiac failure chronic02.05.01.0090.000533%Not Available
Ewing's sarcoma16.29.03.004; 15.09.03.0150.000139%Not Available
Hepatic infarction24.04.07.007; 09.01.06.0170.000139%Not Available
Leiomyosarcoma16.33.07.001; 15.09.03.0160.000799%Not Available
Leiomyosarcoma metastatic16.33.07.002; 15.09.03.0170.000278%Not Available
Metastases to bone16.22.02.005; 15.09.03.0060.002131%Not Available
Metastases to lymph nodes16.22.02.006; 01.09.01.0150.000208%Not Available
Nephroblastoma16.08.02.005; 20.01.04.0110.000208%Not Available
Nuclear magnetic resonance imaging abnormal13.18.03.0030.000533%Not Available
Squamous cell carcinoma of the oral cavity16.13.07.006; 07.21.07.0090.000139%Not Available
The 24th Page    First    Pre   24 25    Next   Last    Total 25 Pages